The German company CureVac dropped more than 50% in the extended session Wednesday after the company said its COVID-19 vaccine candidate is 47% effective in preventing the disease. The trial, which included 40,000 volunteers in Latin America and Europe, estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent, among the lowest reported so far from any Covid-19 vaccine maker. The trial will continue as researchers monitor volunteers for new cases of Covid-19, with a final analysis expected in two to three weeks. The CureVac vaccine is of key importance to Europe, which has preordered 225 million doses, with the option to buy 180 million more.
“While we were hoping for a stronger interim outcome, we recognize that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging,” Chief Executive Franz-Werner Haas said in a statement.
Read more